17 patents
Utility
Combination Treatment of Liver Disorders
4 Jan 24
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a THRβ agonist.
Martijn FENAUX, Kevin KLUCHER, Christopher T. JONES, Thorsten A. KIRSCHBERG
Filed: 20 Jan 23
Utility
Compounds As GLP-1R Agonists
12 Oct 23
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing.
F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX, Corey REEVES, Thorsten A. KIRSCHBERG, Yingzi XU
Filed: 20 Aug 21
Utility
Compounds As GLP-1R Agonists
12 Oct 23
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof.
Corey REEVES, Christopher T. JONES, Kevin QUINN, Gary W. LUEHR
Filed: 23 Feb 23
Utility
THRB Receptor Agonist Compound and Preparation Method and Use Thereof
7 Sep 23
Shanghai YU, Ben LI
Filed: 10 May 23
Utility
Combination Treatment of Liver Disorders
3 Aug 23
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an SSAO inhibitor and a THR-β agonist.
Martijn FENAUX, Kevin KLUCHER, Christopher T. JONES, Thorsten A. KIRSCHBERG, Yujin WANG
Filed: 11 Nov 22
Utility
Compounds As GLP-1R Agonists
25 May 23
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof.
Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX, Gary W. LUEHR
Filed: 25 Oct 22
Utility
Compounds As GLP-1R Agonists
18 May 23
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof.
Corey REEVES, F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX
Filed: 27 Sep 22
Utility
Treatment of Respiratory Disorders
27 Apr 23
Provided herein are compounds for use in treating respiratory disorders.
Martijn FENAUX, Christopher T. JONES, Erin K. QUIRK
Filed: 25 Mar 21
Utility
Treating Liver Disorders
8 Dec 22
Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.
Martijn FENAUX, Yujin WANG, Weidong ZHONG, Kevin KLUCHER
Filed: 6 Nov 20
Utility
Compounds for Inhibiting FGFR4
17 Nov 22
Provided herein are compounds which inhibit FGFR4, compositions thereof, methods of their preparation, and methods for treating disorders mediated by FGFR4 such as cancer.
Yingzi XU, F. Anthony ROMERO
Filed: 18 Jun 20
Utility
Thyroid Hormone Receptor Beta Agonist Compounds
10 Nov 22
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
Filed: 11 Sep 20
Utility
Thyroid Hormone Receptor Beta Agonist Compounds
3 Nov 22
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
Filed: 30 Jun 22
Utility
Thyroid Hormone Receptor Beta Agonist Compounds
8 Sep 22
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
Filed: 21 Aug 20
Utility
Compounds As GLP-1R Agonists
24 Mar 22
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing.
F. Anthony ROMERO, Christopher T. Jones, Martijn FENAUX
Filed: 20 Aug 21
Utility
Combination Treatment of Liver Disorders
9 Dec 21
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and an SSAO inhibitor.
Martijn FENAUX, Kevin KLUCHER, Christopher T. JONES
Filed: 12 May 21
Utility
Combination Treatment of Liver Disorders
9 Dec 21
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a THRβ agonist.
Martijn FENAUX, Kevin KLUCHER, Christopher T. JONES, Thorsten A. KIRSCHBERG
Filed: 12 May 21
Utility
Treating Liver Disorders
12 Aug 21
Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.
Randall HALCOMB, Weidong ZHONG, Martijn FENAUX
Filed: 30 Aug 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first